Reading INDV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INDV free→Reading INDV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INDV free→QuarterlyIQ Insights · INDV
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) Effective June 1, 2026, Indivior Pharmaceuticals, Inc. (the "Company" or the "Registrant") will eliminate the position of Chief Scientific Officer. Dr. Christian Heidbreder will continue to report to the CEO in an advisory capacity on special projects through the end of 2026. Dr. Heidbreder's employment will terminate on December 31, 2026, and…
Other. On May 4, 2026 the Company issued a press release announcing that it had entered into an accelerated share repurchase agreement (the “ASR Agreement”) with an investment bank counterparty (the “Counterparty Bank”) to repurchase $175.0 million (the “Prepayment Amount”) of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), as part of the Company’s previously announced $400 million share repurchase program (the “Share Repurchase Program”). The full text…
Results of Operations and Financial Condition. On April 30, 2026, Indivior Pharmaceuticals, Inc. (“Indivior” or the “Company”) issued a press release reporting its financial results for the period ended March 31, 2026. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The disclosure set forth in
Termination of a Material Definitive Agreement On March 17, 2026, the Company used a portion of the proceeds of the Convertible Notes Offering to prepay all outstanding principal, accrued interest, and associated fees under that Note Purchase Agreement fir st made as of November 4, 2024, by and among by and among RBP Global Holdings Limited, Indivior Global Holdings Limited, Piper Sandler Finance LLC, as Administrative Agent and the lenders from time to time party thereto, as amended by that…
Entry Into a Material Definitive Agreement. Indenture On March 17, 2026, Indivior Pharmaceuticals, Inc. (the “ Company ”) issued $500,000,000 principal amount of its 0.625% Convertible Senior Notes due 2031 (the “ Notes ”; the “ Convertible Notes Offering ”). The Notes were issued pursuant to, and are governed by, an indenture (the “ Indenture ”), dated as of March 17, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “ Trustee ”). Pursuant to the pu…
The Notes were issued to the initial purchasers in reliance upon Section 4(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act ”), in transactions not involving any public offering. The Notes were resold by the initial purchasers to persons whom the initial purchasers reasonably believed are “qualified institutional buyers,” as defined in, and in accordance with, Rule 144A under the Securities Act. Any shares of the Company’s common stock that may be issued upon conversion o…
Other Events. On March 12, 2026, the Company announced the pricing of its offering of 0.625% convertible senior notes due 2031 (the “Notes”). A copy of the press release is filed as 99.1 to this Current Report on Form 8-K. Neither this Current Report on Form 8-K nor the press release constitutes an offer to sell, or the solicitation of an offer to buy, the Notes or the shares of the Company’s common stock, if any, issuable upon conversion of the Notes.
Other Events. On March 12, 2026, the Company announced the launch of its proposed offering of convertible senior notes due 2031 (the “Notes”). A copy of the press release is filed as 99.1 to this Current Report on Form 8-K. Neither this Current Report on Form 8-K nor the press release constitutes an offer to sell, or the solicitation of an offer to buy, the Notes or the shares of the Company’s common stock, if any, issuable upon conversion of the Notes.
Results of Operations and Financial Condition. On February 26, 2026, Indivior Pharmaceuticals, Inc. (“Indivior” or the “Company”) issued a press release reporting its financial results for the period ended December 31, 2025. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Importance-ranked changes since the prior daily snapshot.
Valuation rose by 10.4 points (from 34.3 to 44.7).
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.